Atopic dermatitis
Conditions
Interventions
After approval of the research project by the Research Ethics Committee UNIFESP and signing of the Informed Consent Form and Assent Form (under eighteen years), fifty patients with mild atopic dermati
calculation of SCORAD
capture of photographs and evaluation of disease activity perception using the Visual Analog Scale by the research participant. After the end of treatment, participan
E04.936.537
Sponsors
Universidade Federal de São Paulo
Universidade Federal de São Paulo
Eligibility
Age
1 Years to 14 Years
Inclusion criteria
Inclusion criteria: Signature of the Informed Consent Form (ICF) and Assent Form before any study procedures; Patients of any gender, aged one to fourteen years old; Clinical diagnosis of mild atopic dermatitis (SCORAD less or equal to 20). Eczematous lesions present in the antecubital fossae
Exclusion criteria
Exclusion criteria: Patients or guardians who do not agree with the study conditions or lack the capacity to understand and strictly follow the received instructions, without availability to attend reassessments, or who refuse to sign the Informed Consent Form (ICF) and Assent Form; non-agreement to sign the Photography Authorization Form will not be a reason for exclusion from the study; Pregnant or lactating women; Moderate and severe atopic dermatitis; Immunosuppression or genodermatoses, such as Netherton syndrome; Chlorine bath in the last week; Use of topical corticosteroids or calcineurin inhibitors in the last two weeks; Use of topical or oral antibiotics in the last thirty days; Use of oral immunosuppressive medications in the last thirty days; Use of immunobiologics in the last sixteen weeks; Use of phototherapy in the last thirty days; Active bacterial, viral, or fungal skin infections; Hypersensitivity to any component of the formulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the reduction of S. aureus bacteria concentration and increase of S. epidermidis bacteria concentration on the injured skin in the antecubital fossae with the use of a new moisturizing cream | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of SCORAD by more than 50%; Clinical improvement as perceived subjectively by the patient through the Visual Analog Scale; Absence of adverse events or occurrence of mild adverse events | — |
Countries
Brazil
Contacts
Public ContactHeloísa Freixo
Universidade Federal de São Paulo
Outcome results
None listed